C-Peptide: Clinical Significance and Treatment Guidance
C-peptide measurement is primarily indicated to distinguish between type 1 and type 2 diabetes in ambiguous cases, particularly when islet autoantibodies are absent, and should be measured beyond 3 years after diagnosis when diabetes type remains uncertain. 1
Primary Clinical Indications
Measure C-peptide when:
- Diabetes type is uncertain, especially in adults without islet autoantibodies 1
- Considering transition from insulin to non-insulin therapies in insulin-treated patients 1
- Clinically diagnosed type 1 diabetes of ≥3 years duration (leads to reclassification in 11% of cases) 1
- Differentiating between type 1 diabetes and monogenic diabetes (MODY) in young-onset diabetes 1
Do NOT measure C-peptide:
- Within 2 weeks of hyperglycemic emergency 1
- Within 12 hours of severe hypoglycemia 1
- For routine care in most people with diabetes 2
Critical Interpretation Thresholds
For Treatment Decisions:
C-peptide >600 pmol/L (>1.8 ng/mL):
- Strongly suggests type 2 diabetes 1
- Patients can often transition to non-insulin therapies 1
- Indicates preserved endogenous insulin secretion
C-peptide <200 pmol/L (<0.6 ng/mL):
- Confirms type 1 diabetes 1
- Indicates severe insulin deficiency requiring insulin therapy
C-peptide 200-600 pmol/L (0.6-1.8 ng/mL):
- Usually consistent with type 1 diabetes 1
- May occur in insulin-treated type 2 diabetes, particularly with normal/low BMI or long disease duration 1
- Retesting may be required as C-peptide declines more slowly in adults than children 1
Proper Testing Methodology
Measurement requirements:
- Measure alongside concurrent glucose concentration within 5 hours of eating 1
- If concurrent glucose <4 mmol/L (<72 mg/dL) AND C-peptide <600 pmol/L (<1.8 ng/mL), repeat the test 1
- Random non-fasting C-peptide is acceptable and convenient 3
Timing Considerations
Optimal timing for diabetes classification:
- Beyond 3 years after diagnosis provides best discriminative value 1
- C-peptide levels fall progressively in type 1 diabetes, becoming low or undetectable by 3 years 1
- Earlier testing has utility but normal values do NOT exclude type 1 diabetes in adults shortly after diagnosis 1
Why timing matters:
- Adults have higher C-peptide at diagnosis than children 1
- C-peptide declines more slowly in adults 1
- Low C-peptide confirms insulin deficiency, but normal C-peptide does not exclude type 1 diabetes early in disease course 1
Impact on Clinical Outcomes
Low C-peptide levels (even >10 pmol/L) are clinically significant:
- Associated with increased risk of diabetic complications (nephropathy, neuropathy, retinopathy, foot ulcers) 4
- Correlated with poorer glycemic control (higher HbA1c) 4
- Linked to severe hypoglycemia risk 4
- Even minimal residual C-peptide provides clinical benefit 4
Important Caveats and Pitfalls
False elevations occur in:
- End-stage renal failure (altered clearance) 1
Assay limitations:
- Significant variability exists between commercially available C-peptide assays 1
- Standardization efforts are underway but not yet complete 1
- This limits clinical utility of defined cutoff values 1
Other conditions with low C-peptide:
- Post-pancreatectomy diabetes 1
- Immune checkpoint inhibitor-induced diabetes 1
- Some secondary diabetes types (e.g., pancreatitis) 1
- Very long-standing type 2 diabetes 1
- These conditions require similar treatment to type 1 diabetes 1
Limited Role in Type 2 Diabetes
Routine C-peptide testing is NOT recommended for:
- Most people with type 2 diabetes 2
- Insulin resistance confounds interpretation 5, 6
- May be elevated due to compensatory hyperinsulinemia 5, 6
Exception: Consider when evaluating potential transition off insulin therapy in insulin-treated patients where diabetes type is uncertain 1
Monogenic Diabetes Screening
Consider monogenic diabetes when: